Generic placeholder image

Recent Patents on Anti-Infective Drug Discovery


ISSN (Print): 1574-891X
ISSN (Online): 2212-4071

Update On Emerging Antivirals For The Management Of Herpes Simplex Virus Infections: A Patenting Perspective

Author(s): Aswani D. Vadlapudi, Ramya K. Vadlapatla and Ashim K. Mitra

Volume 8, Issue 1, 2013

Page: [55 - 67] Pages: 13

DOI: 10.2174/1574891X11308010011

Price: $65


Herpes simplex virus (HSV) infections can be treated efficiently by the application of antiviral drugs. The herpes family of viruses is responsible for causing a wide variety of diseases in humans. The standard therapy for the management of such infections includes acyclovir (ACV) and penciclovir (PCV) with their respective prodrugs valaciclovir and famciclovir. Though effective, long term prophylaxis with the current drugs leads to development of drug-resistant viral isolates, particularly in immunocompromised patients. Moreover, some drugs are associated with dose-limiting toxicities which limit their further utility. Therefore, there is a need to develop new antiherpetic compounds with different mechanisms of action which will be safe and effective against emerging drug resistant viral isolates. Significant advances have been made towards the design and development of novel antiviral therapeutics during the last decade. As evident by their excellent antiviral activities, pharmaceutical companies are moving forward with several new compounds into various phases of clinical trials. This review provides an overview of structure and life cycle of HSV, progress in the development of new therapies, update on the advances in emerging therapeutics under clinical development and related recent patents for the treatment of Herpes simplex virus infections.

Keywords: Emerging therapeutics, infections life cycle, Herpes simplex virus, recent patents, treatment, Viral Entry, ANTI-HSV DRUGS, sacral ganglia, Valomaciclovir, Fusion Peptidic Inhibitors

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy